Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNelly Brianden_US
dc.contributor.authorSophie Le Coeuren_US
dc.contributor.authorGonzague Jourdainen_US
dc.contributor.authorSomboon Hotrawarikarnen_US
dc.contributor.authorSurat Sirinontakanen_US
dc.contributor.authorTemsiri Hinjiranandanaen_US
dc.contributor.authorSuparat Kanjanavaniten_US
dc.contributor.authorPatrinee Traisathiten_US
dc.contributor.authorKenneth McIntoshen_US
dc.contributor.authorMarc Lallemanten_US
dc.description.abstractThe evolution of hematological parameters in HIV-1-exposed uninfected infants according to various durations of perinatal zidovudine exposure was studied. We used data prospectively collected among 1122 HIV-uninfected formula-fed infants born to HIV-infected mothers who participated in a clinical trial to prevent perinatal transmission in Thailand (PHPT-1). Infants were exposed to different durations of zidovudine both in utero and after birth. Hemoglobin level and leukocyte, absolute neutrophil, and lymphocyte counts were measured at birth and at 6 weeks of age. The association between hematological parameters at birth and the duration of zidovudine exposure in utero was studied using a linear regression model, and changes between birth and 6 weeks of age and the duration of postnatal zidovudine exposure using mixed effects models. At birth, the hemoglobin level was lower in newborns exposed to zidovudine for more than 7.5 weeks in utero (adjusted regression coefficient: -0.6g/dl; 95% confidence interval: -1.1 to -0.1). Six weeks after birth, the hemoglobin level had decreased faster in infants administered zidovudine for more than 4 weeks (adjusted regression coefficient: -0.1 g/dl; 95% confidence interval: -0.2 to -0.1). The duration of perinatal zidovudine exposure was not associated with the evolution of leukocyte, neutrophil, and lymphocyte counts. Despite the differences in hemoglobin levels, grade 3 or 4 anemia did not significantly differ by maternal or infant zidovudine duration. The clinical impact appeared modest, but longer exposure may warrant close monitoring. Copyright 2010, Mary Ann Liebert, Inc.en_US
dc.subjectImmunology and Microbiologyen_US
dc.titleHematological safety of perinatal exposure to zidovudine in uninfected infants born to HIV type 1-infected women in Thailanden_US
article.title.sourcetitleAIDS Research and Human Retrovirusesen_US
article.volume26en_US Institut National d' Etudes Demographiquesen_US of research for development, Thailanden_US Mai Universityen_US Paris Descartesen_US School of Public Healthen_US Hospitalen_US Promotion Hospital Regional Center ien_US Pranangchao Sirikit Hospitalen_US Hospitalen_US Medical Schoolen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.